Quest Diagnostics Inc Stock Price, News & Analysis

Quest Diagnostics (NYSE: DGX), a leading diagnostic information services provider, has scheduled the release of its Q2 2025 financial results for July 22, 2025, before market opening. The company will host a conference call at 8:30 a.m. Eastern Time to discuss the results. Participants can join via phone using specific dial-in numbers for U.S./Canada (888-455-0391) and international callers (773-756-0467) with passcode "7895081". The earnings release and webcast will be available on Quest's investor website. A replay will be accessible until August 5, 2025, through the website or dedicated phone numbers. The company recommends reviewing their SEC periodic reports for risk factors and historical financial information.

Quest Diagnostics (NYSE: DGX) has announced a collaboration with MD Anderson Cancer Center to develop a novel Multi-cancer Stratification Test (MCaST) blood test. The test will assess elevated risk for multiple cancers including colorectal, lung, breast, pancreatic, ovarian, liver, prostate, esophageal and stomach cancers. Based on technology developed by Dr. Samir Hanash's team at MD Anderson, the test uses circulating protein biomarkers and was validated through extensive clinical research involving tens of thousands of individuals. Quest plans to commercialize the test in North America by 2026, positioning it as a supplement to conventional screening methods. The test aims to provide a more accessible, affordable alternative to current screening methods, addressing the concerning statistic that only 51% of U.S. adults undergo routine medical appointments or cancer screenings annually.

Quest Diagnostics' second "Know Your Health" survey reveals concerning gaps in Americans' health awareness. The survey of 2,100 U.S. adults found that 40% know their streaming passwords by heart, while only 19% know their cholesterol scores. While 92% of Americans actively prepare for future health needs, many face barriers to healthcare access. Notably, 37% reported obstacles in receiving medical care, with higher percentages among younger generations. The survey highlighted that 30% of Americans feel their healthcare providers don't adequately discuss prevention and wellness. Despite these challenges, 70% of Americans rate their health as good or excellent, with sleep (71%), hydration (65%), and exercise (62%) being top health priorities. The study also revealed that 63% of Americans are unaware they can purchase lab tests without a doctor's visit, highlighting opportunities for Quest's consumer-initiated testing platform.

Quest Diagnostics (NYSE: DGX) announced that Chairman, CEO and President Jim Davis will deliver a presentation at the William Blair 45th Annual Growth Stock Conference in Chicago. The presentation is scheduled for June 3, 2025, at 11:00 a.m. Eastern Time.

During the presentation, Davis will discuss the company's strategy, performance, and current market trends. Investors can access the live webcast through Quest's investor relations page at ir.QuestDiagnostics.com. The archived version will be available within 24 hours after the event and remain accessible until July 3, 2025.

[]

Quest Diagnostics (NYSE: DGX), a leading diagnostic information services provider, has announced a quarterly cash dividend of $0.80 per share. The dividend will be paid on July 21, 2025, to shareholders who are on record as of July 7, 2025. This regular dividend declaration demonstrates Quest's commitment to providing consistent returns to its shareholders.

A new Quest Diagnostics (DGX) report reveals concerning trends in cancer care, with 76% of oncologists reporting increased advanced cancer cases. Among these, 75% attribute this rise to screening barriers. The report highlights significant challenges in detecting cancer recurrence, with 79% of oncologists encountering cases where recurrence was missed in earlier stages. Key findings show that 68% of cases were missed due to delayed follow-up care, while 50% cite limitations in current imaging tests. The study emphasizes the potential of circulating tumor DNA (ctDNA) minimal residual disease (MRD) testing, with 94% of oncologists believing it could reduce diagnosis delays. Quest's Haystack MRD™ test has shown promising results, detecting treatment response 1.4 months faster than traditional methods. However, broader adoption faces barriers including insurance coverage and the need for more clinical evidence.

Quest Diagnostics (NYSE: DGX) reported strong Q1 2025 financial results with revenues of $2.65 billion, up 12.1% from 2024. The company achieved reported diluted EPS of $1.94 (up 12.8%) and adjusted diluted EPS of $2.21 (up 8.3%).

Key performance metrics include:

• Diagnostic Information Services revenues increased 12.7% to $2.59 billion
• Operating income rose 15.4% to $346 million
• Net income grew 13.2% to $220 million
• Cash from operations doubled to $314 million

Quest reaffirmed its full-year 2025 guidance with:

• Expected revenues between $10.70-10.85 billion
• Projected revenue growth of 8.4-9.9%
• Updated reported diluted EPS guidance of $8.62-8.87
• Maintained adjusted diluted EPS guidance of $9.55-9.80

Quest Diagnostics (NYSE: DGX) has launched AD-Detect™, a new laboratory blood test designed to confirm amyloid brain pathology in Alzheimer's disease patients with mild cognitive impairment or dementia. The test combines blood levels of amyloid beta 42/40 and p-tau217 to produce the AD-Detect Likelihood Score™.

Research presented at the 2025 AAN Annual Meeting demonstrated the test's 91% sensitivity and specificity, with positive and negative predictive values of 89% in mild cognitive impairment populations. The test showed strong performance in real-world specimens, categorizing 42% as high likelihood, 51% as low likelihood, and 7% as indeterminate for PET positivity.

The test is now available nationwide (except New York) through Quest's network of approximately 8,000 patient access points. This blood-based test offers a more affordable and less invasive alternative to traditional amyloid PET imaging and cerebral spinal fluid testing.

Quest Diagnostics (NYSE: DGX) has launched a new FDA-cleared HPV self-collection solution for cervical cancer screening. The service allows patients to collect their own specimens in healthcare settings and will be available at Quest's 2,000 patient service centers starting next month.

The solution utilizes Roche's FDA-cleared HPV self-collection technology, approved for use with their cobas® HPV test in May 2024. This initiative follows Quest's successful launch of self-collection services for STIs in October 2024.

The self-collection option comes at no extra charge and aims to address the declining screening rates, with 4.4 million fewer American women receiving screenings in 2021 compared to 2019. The service is not FDA approved for at-home collection and is not intended to replace regular pelvic examinations.